AAPL 220.21 1.0601% MSFT 369.93 -2.3416% NVDA 105.5856 -3.7243% GOOGL 153.14 -0.7711% GOOG 154.91 -0.7369% AMZN 188.5543 -2.1615% META 569.4501 -1.264% AVGO 164.5095 -2.7262% LLY 810.54 -1.4553% TSLA 254.692 -3.361% TSM 164.16 -0.6596% V 346.255 0.9931% JPM 243.015 0.0679% UNH 522.675 1.2858% NVO 68.6962 0.7264% WMT 86.76 1.8908% LVMUY 123.56 -2.3087% XOM 119.655 1.6351% LVMHF 616.1 -2.7551% MA 541.65 0.1924%
AAPL 220.21 1.0601% MSFT 369.93 -2.3416% NVDA 105.5856 -3.7243% GOOGL 153.14 -0.7711% GOOG 154.91 -0.7369% AMZN 188.5543 -2.1615% META 569.4501 -1.264% AVGO 164.5095 -2.7262% LLY 810.54 -1.4553% TSLA 254.692 -3.361% TSM 164.16 -0.6596% V 346.255 0.9931% JPM 243.015 0.0679% UNH 522.675 1.2858% NVO 68.6962 0.7264% WMT 86.76 1.8908% LVMUY 123.56 -2.3087% XOM 119.655 1.6351% LVMHF 616.1 -2.7551% MA 541.65 0.1924%

small-cap

One NASDAQ- Listed Biotechnology Stock at Resistance Level: XCUR

Mar 27, 2025 | Team Kalkine
One NASDAQ- Listed Biotechnology Stock at Resistance Level: XCUR
Image source: shutterstock

XCUR:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Exicure, Inc. (NASDAQ: XCUR)

Exicure, Inc. (NASDAQ: XCUR) is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. As per our previous US Dailies report published on ‘XCUR’ on 4th March 2025, Kalkine provided an Speculative Buystance on the stock at USD 14.03 based on fundamental analysis and the stock price has now moved by ~ 23.93% since then and is trading above resistance 2.

Noted below are the details of support and resistance levels provided in our previous report:

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.